LACK OF EFFECT OF OMEPRAZOLE TREATMENT ON STEADY-STATE PLASMA-LEVELS OF METOPROLOL

被引:31
作者
ANDERSSON, T
LUNDBORG, P
REGARDH, CG
机构
[1] Research Laboratories, Mölndal, AB Hässle
关键词
OMEPRAZOLE; SUBSTITUTED BENZIMIDAZOLE; METOPROLOL; INTERACTION; CYTOCHROME-P450; DEBRISOQUINE HYDROXYLASE; PHARMACOKINETICS; ADVERSE EFFECTS;
D O I
10.1007/BF00315140
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In a randomised double-blind crossover study, seven healthy males were concomitantly given metoprolol 100 mg o.d. as a controlled release formulation, and omeprazole 40 mg o.d. or placebo, for 8 days. Plasma levels of the R- and S-enantiomers of metoprolol were determined on the 8th day of each treatment. The subjects were also characterised by their metabolic capacity to hydroxylate debrisoquine. Concomitant omeprazole treatment had no significant influence on the steady-state plasma levels of the two enantiomers of metoprolol. All subjects were characterised by extensive debrisoquine hydroxylation, i.e. extensive metoprolol metabolism. As metoprolol is metabolised to a great extent by debrisoquine hydroxylase (IID6), it is concluded that concomitant omeprazole treatment will probably have a negligible influence on the metabolism of the relatively large number of drugs mainly metabolised by this isoenzyme of the cytochrome P450 family.
引用
收藏
页码:61 / 65
页数:5
相关论文
共 33 条
[1]   A STUDY OF THE INTERACTION BETWEEN OMEPRAZOLE AND PHENYTOIN IN EPILEPTIC PATIENTS [J].
ANDERSSON, T ;
LAGERSTROM, PO ;
UNGE, P .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :329-333
[2]   EFFECT OF OMEPRAZOLE AND CIMETIDINE ON PLASMA DIAZEPAM LEVELS [J].
ANDERSSON, T ;
ANDREN, K ;
CEDERBERG, C ;
EDVARDSSON, G ;
HEGGELUND, A ;
LUNDBORG, P .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (01) :51-54
[3]   EFFECT OF OMEPRAZOLE TREATMENT ON DIAZEPAM PLASMA-LEVELS IN SLOW VERSUS NORMAL RAPID METABOLIZERS OF OMEPRAZOLE [J].
ANDERSSON, T ;
CEDERBERG, C ;
EDVARDSSON, G ;
HEGGELUND, A ;
LUNDBORG, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (01) :79-85
[4]   SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS [J].
ANDERSSON, T ;
REGARDH, CG ;
DAHLPUUSTINEN, ML ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :415-416
[5]   A COMPARISON OF 2 DIFFERENT DOSES OF OMEPRAZOLE VERSUS RANITIDINE IN TREATMENT OF DUODENAL-ULCERS [J].
BARDHAN, KD ;
PORRO, GB ;
BOSE, K ;
DALY, M ;
HINCHLIFFE, RFC ;
JONSSON, E ;
LAZZARONI, M ;
NAESDAL, J ;
RIKNER, L ;
WALAN, A .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1986, 8 (04) :408-413
[6]   IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE [J].
BERTILSSON, L ;
HENTHORN, TK ;
SANZ, E ;
TYBRING, G ;
SAWE, J ;
VILLEN, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :348-355
[7]  
BORG KO, 1975, ACTA PHARMACOL TOX, V36, P125
[8]   CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :537-547
[9]   THE RELATIONSHIP BETWEEN THE BINDING OF 2-NORMAL-ALKYLBENZIMIDAZOLES TO RAT HEPATIC-MICROSOMAL CYTOCHROME-P-450 AND THE INHIBITION OF MONOOXYGENATION [J].
DICKINS, M ;
BRIDGES, JW .
BIOCHEMICAL PHARMACOLOGY, 1982, 31 (07) :1315-1320
[10]   MEPHENYTOIN AND SPARTEINE OXIDATION - GENETIC POLYMORPHISMS IN DENMARK [J].
DROHSE, A ;
BATHUM, L ;
BROSEN, K ;
GRAM, LF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (05) :620-625